© Copyright Nostre Net
Market Forecast
Registering a CAGR of 8.57%, Transarterial Chemoembolization (TACE) Market is expected to grow from USD 1559.20 Million in 2018 to USD 2777.22 Million by 2025.
Hepatocellular carcinoma (HCC) is a primary malignancy of the liver and occurs mainly due to chronic liver disease and cirrhosis. It is the third leading cause of cancer deaths worldwide, with over 500,000 people affected. Transarterial chemoembolization market is the current standard of therapy for patients with intermediate-stage hepatocellular carcinoma (HCC). Conventional TACE is considered as a standard treatment for HCC.
Key Players
Segmentation
By Procedure Type
By Product Type
By End-User
By Region
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Synopsis
Market Research Future (MRFR) asserts that the global urinalysis test market is slated to demonstrate a stellar CAGR during the forecast period (2017-2023). The increased demand for point of care testing devices is likely to favor the market growth. Urinalysis is referred to as a urine test which is performed to detect and manage disorders like liver disease, urinary tract infections, diabetes, and kidney disease. A cost-effective and non-invasive analysis method, urinalysis involves checking the content, appearance, and concentration of the urine. These kinds of tests are highly recommended during a routine examination, pregnancy checkup, and pre-surgery preparation in order to detect any disease condition.
Market Potential and Pitfalls
The urinalysis market is growing at breakneck speed due to the rising demand for point of care testing devices, developing technologies in the field of diagnostics, and increased prevalence of chronic diseases across the globe. The cost-effectiveness along with the augmenting demand for urine automated urine analyzers are acting as push factors for the growth of the market. As per the National Institute of Diabetes and Digestive and Kidney Diseases, the prevalence of chronic kidney disease among the general population is about 14%. The urinalysis market has undergone several technological advancements which are further anticipated to boost the market across the globe as such advancements have proved to improve the reliability and efficiency of the results. Moreover, urine analyzers are integrated with Electronic Health Records in order to link the results directly into the database of the patient. Siemens AG has collaborated with Relaymed in order to bring labs cloud-based connectivity for Clinitek Status POC instruments and the Siemens DCA Vantage analyzer. With the change in lifestyle and increasing incidences of chronic diseases, there is an increased demand for advanced and quick tests, which has further resulted in the growth of the market.
Competitive Dashboard
The prominent players operating in the urinalysis test market are Dahaner (U.S.), ARKRAY Inc. (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Sysmex Corporation (Japan), Siemens AG (U.S.), Bio-Rad Laboratories Inc. (U.S.), and ACON Laboratories Inc. (U.S.).
Global Urinalysis Test Market: Segmental Analysis
The global urinalysis test market has been segmented on the basis of test type, product type, end user, and application.
By mode of product type, the global urinalysis test market has been segmented into consumables and instruments. Among these, the consumables are expected to hold a significant share in the global market owing to its extensive use in the disposables in urinalysis research and testing. Moreover, the advent of advanced reagents and use of disposables are likely to favor the growth of the segment.
By mode of test type, the global urinalysis test market has been segmented into biochemical urinalysis, macroscopic urinalysis, urinalysis analyzer and sediments/microscopic urinalysis. Among these, the biochemical urinalysis is likely to occupy a significant share owing to the rapidly increasing geriatric population coupled with the increased incidences of kidney diseases and urinary tract infections.
By mode of application, the global urinalysis test market has been segmented into disease diagnosis comprising diagnosis of diseases like liver disease, kidney disease, pregnancy tests, diabetes, and others.
By mode of end-users, the global urinalysis test market has been segmented into independent laboratories, hospitals, and physician practices.
Regional Insights
Geographically, the urinalysis test market span across regions namely, Europe, America, Asia Pacific, and the Middle East & Africa.
Considering the global scenario, America is considered to occupy the largest market share due to the increased demand for automated urine analyzers, accelerating incidences of liver and kidney diseases, and technological advancements in this region. In the North American region, the U.S. is estimated to hold the major share due to the high concentration of market giants manufacturing consumables and urine analyzers.
Europe occupies the second position and is anticipated to expand at a steady pace. The growth is credited to the rising prevalence of chronic diseases such as diabetes. Moreover, the availability of cost-effective treatment coupled with the rising funding from the government for R&D activities is further triggering the demand for urinalysis test in this region.
The Asia Pacific is presumed to grow at the fastest rate due to the augmenting incidences of chronic diseases such as kidney, diabetes, and others. Moreover, with the changing lifestyle and increasing demand for urine analyzers, the market is likely to boom in this region.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Analysis
The global healthcare enterprise software market is expected to touch USD 76.45 billion at a staggering 13.0 % CAGR during the forecast period. Healthcare software is used by nursing homes and hospitals for managing data both clinical and non-clinical. It helps in maintaining patient records electronically resulting in hassle-free storage and retrieval. Such software aids in managing, securing and analyzing information precisely in healthcare environment. Ample data can be stored here rather than handling records manually.
There are abundant factors that is propelling the growth of the healthcare enterprise software market. These factors as per the MRFR (Market Research Future) report include increase in software solutions available exclusively for healthcare management, increasing global competition, increasing awareness about enterprises software, introduction of new software services, technological advancement and innovation, entry of novel industry players, increasing number of enterprises across the world, strict rule governing the patient information management and attention on electronic health records. On the contrary, price of the software solution is likely to impede the growth of the many healthcare facilities now use voice recognition software for transcription.
Key Players
Leading players profiled in the healthcare enterprise software market include CompuGroup (UK), Medidata Solutions (US), Athenahealth (US), Cerner Corporations (US), McKesson Corporation (US), Infosys Ltd. (U.S), Cognizant Technology Solutions Corporation (U.S.), IBM Corporation (U.S), Allscripts Healthcare Solutions (U.S), and Microsoft Corporation (U.S).
Market Segmentation
MRFR report offers a broad segmental analysis of the healthcare enterprise software market on the basis of types, mode of delivery, applications and end users.
Based on types, it is segmented into billing, HR management software, laboratory management software, OT management software, scheduling software, inventory management software, patient registration software and others.
Based on mode of delivery, the healthcare enterprise software market is segmented into cloud base and on-premise.
Based on application, it is segmented into non-clinical, clinical and others.
Based on end users, the healthcare enterprise software market is segmented into pharmacy, clinics, hospitals and others.
Regional Analysis
By region, the healthcare enterprise software market covers growth opportunities and latest trends across Americas, Europe, Asia Pacific and Middle East and Africa. Of these, Americas will remain the largest market over the forecast period owing to growing need for software solutions to manage patient’s medical records coupled with increasing utilization of information technology (IT) in hospitals. Factors that are imparting towards the growth of the healthcare enterprise software market in this region include extensive utilization of software solutions for healthcare management, use of electronic records over manual records, growing significance of electronic health records, advancement in technology in software development, health record maintenance, awareness amid patients regarding significance of their medical records as well as, legal applications, and demand for software solutions that are user friendly. In the US the leading healthcare IT and medical device companies are global leaders in offering healthcare software solutions and manufacturing medical components and devices. The healthcare enterprise software market in Europe will have the second major share due to rise in use of IT for healthcare management. This market is expanding constantly and catching up slowly with the market in North America. In the APAC region, the healthcare enterprise software market is expected to grow at the fastest pace owing to increasing awareness regarding the software coupled with use of electronic records over manual records. Diagnostic devices are showing an increasing and positive growth in the market. Toshiba Medical Systems Corporation is one of the key market players in this region. The demand for healthcare outreaching supplies, population growth and increasing disease burden is driving the growth of the market in this region. On the other hand, the healthcare enterprise software market in the Middle East and Africa is anticipated to show a steady growth over the forecast period.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Overview:
Amniotic membrane is quite important for body to initiate healing. It is a combination of tissues and cells, which acts as a foundation for re-growth of soft tissues. Amniotic membrane has wide-scale utility in eye surgery that acts like a biological bandage. The process heals or replaces eye tissues that are damaged. The global amniotic membrane market is all set to garner USD 1,210.9 million during the forecast period (2018-2023) with a CAGR of 12.16%. Market Research Future (MRFR) declared the possibility for the amniotic membrane market exceeding the predicted valuation is quite high.
The amniotic membrane market can rely on substantial surge in amniotic membrane-based transplantations globally. Also, health-related awareness is on the rise, which is expected to spur the global market growth.
Competitive Landscape:
Several companies are experiencing substantial growth due to the surge in the ingress level of the amniotic membrane market. These companies have been profiled by MRFR in their report on the same market for a better understanding of strategic moves and trends that can inspire market change. These companies are Applied Biologics (US), Alliqua BioMedical, Inc. (US), Integra LifeSciences (US), Skye Biologics Inc. (California), MiMedx (US), Amniox Medical, Inc. (Florida), Katena Products, Inc. (US), Human Regenerative Technologies, LLC (US), Amnio Technology, LLC (US), and Osiris Therapeutics, Inc. (US).
Segmentation:
MRFR’s analysis of the amniotic membrane market is based on an extensive segmentation that includes type, application, and end-user. This segmentation gets solid backup from the value-wise and volume-wise analysis of the market.
Based on the type, the global amniotic membrane market can be segmented into cryopreserved and lyophilized. traditional therapy was followed by placement of a dehydrated amniotic membrane allograft and the healing time course was documented with charted measurements. The cryopreservation amniotic membrane segment has better potential to lead the market with an impressive CAGR to reach USD 1,090.08million by the end of 2023. This is expected to get driven by the rising number of ocular surgeries. The lyophilized amniotic membrane segment, on the other hand, can project the highest CAGR of 14.18% during the forecast period. This growth is expected to rely mostly on rising number of surgeries, reconstruction procedures, cosmetic surgeries, and venous & pressure leg ulcers.
Based on the application, the global amniotic membrane market can be segmented into surgical wounds, ophthalmology, stem cell biology, regenerative medicine, and others. The ophthalmology segment is expected to fetch in substantial market due to wide-scale use of amniotic membrane in the segment.
Based on the end-user, the amniotic membrane market can be segmented into hospitals & clinics and others. The hospitals & clinics segment is expected to gain more as patients prefer the segment more.
Regional Analysis:
MRFR in their region-specific take on the global amniotic membrane market includes namely, the Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA). This region-specific segmentation allows a closer look at the growth pockets that unravels later market possibilities.
The Americas had the largest market share and it covered around 37.6% in 2017 and at present, it is slated to score an impressive CAGR of 13.28%during the forecast period. The APAC market is geared up to record the fastest CAGR during the forecast period. It has a huge market potential and can achieve 13.60% CAGR during the forecast period.
Europe has the potential to surpass USD 681.71 million valuation by 2023. Several issues like pterygium, cicatricial pemphigoid & Stevens-Johnson syndrome, conjunctival surface reconstruction, persistent epithelial defects with ulceration, and ocular surface reconstruction in patients with chemical & thermal burns in Europe are steering the amniotic membrane market growth in Europe. Germany makes a major impact and France is following Germany’s lead.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013,
United States of America
The global diabetic ulcer treatment market is expected to display a CAGR of 8.5% over the forecast period. It was valued at USD 7500 million in 2018. The large healthcare expenditure of nations in Europe, Americas, and other developing countries can drive the diabetic ulcer treatment market growth exponentially. Rising number of diabetics has driven the need for diabetic ulcer treatment. According to the American College of Physicians, diabetic foot ulcers statistics accounted to 6.3% cases annually. Standards outlined by healthcare organizations for getting annual foot exams annually can work in favor of the diabetic ulcer treatment market.
Diabetic ulcers are open wounds that appear in diabetics at the bottom of their foot. It is most commonly found in older men. Treatment of ulcers and amputations caused by these cost massive hospitalization fees and has triggered the need for effective therapies and methods. The global diabetic ulcer treatment market report by Market Research Future (MRFR) looks at amputations and neurological indications of these ulcers and predicts the future of their treatments for the period of 2019 to 2025 (forecast period).
Diabetic Ulcer Treatment Market Competitive Outlook
Cardinal Health, Integra LifeSciences Corporation, ACELITY L.P. INC., Essity Aktiebolag, Smith & Nephew PLC, Organogenesis Inc., Mölnlycke Health Care AB, Braun Melsungen AG, SANUWAVE Health, Inc., ConvaTec Group PLC, and 3M are some of the notable players profiled in the global diabetic ulcer treatment market. Mergers, new product launches, and acquisitions are prime strategies of the players in the market. Recently, Organogenesis Holdings Pvt Ltd. has launched biomaterials in an effort to expand its wound dressing product line and to appeal to patient demand. Clinical trials are also being conducted to test the efficacy and performance of treatments.
Diabetic Ulcer Treatment Market Segmentation
The Global Diabetic ulcer treatment market has been segmented by type, treatment, and end-user.
By type, Diabetic Ulcer Treatment Market has been divided into foot ulcer and mouth ulcer. The foot ulcer segment accounted for a large share of the global market. The primary factor driving the segment growth is the complications arising due to diabetes mellitus and the large pool of patients. Use of wound dressings and biologics for lowering the rate of amputations and successful treatment of DFU can drive the diabetic foot ulcer market during the forecast period.
By treatment, the diabetic ulcer treatment market is segmented into active therapies, wound care dressings, diabetic foot ulcer treatment products and wound care devices. Wound dressing held the largest share of the market due to the large number of diabetics.
By end-user, the diabetic ulcer treatment market is segmented into academic and research organizations, hospitals and clinics, and ambulatory surgical centers. Hospitals and clinics accounted for the largest market share due to awareness campaigns by governments and favorable reimbursement schemes. Launch of mobile applications for creating awareness among the masses has successfully driven patients towards hospitals and clinics for diabetic ulcer treatment.
Diabetic Ulcer Treatment Market Regional Analysis
Europe, Asia Pacific (APAC), the Middle East & Africa (MEA), and Americas are regions covered with respect to the global diabetic ulcer treatment market.
The Americas can spur the demand for diabetic ulcer treatment due to the large number of cases of diabetics. According to the American Podiatric Medical Association, close to 14-24% of Americans with diabetic foot ulcers have undergone amputations. The high potential of the combination of debridement and continuous diffusion of oxygen (CDO) has seen successful outcomes in treatment of diabetic foot ulcers (DFU).
APAC can display a robust growth rate during the forecast period owing to a large patient pool and the developing healthcare sector in India and China.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013,
United States of America
Cerebral palsy is defined as a group of disorders that affect muscle movement and coordination, which in many cases, impairs vision, hearing, sensation and others senses. Cerebral palsy is a congenital disorder of movement, muscle tone or posture and can affect a person’s posture, balance and ability to move, communicate, eat, sleep and learn. According to the Centre for Disease Control 1 to 4 out of every 1,000 children across the globe are affected by cerebral palsy, thereby creating a strong demand for diagnosis, and treatment for the condition which will drive growth for Cerebral Palsy Treatment Market.
Competitive Overview:
Allergen Plc, Cellular Biomedicine Group, Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline Plc, Abbott Laboratories, Acorda Therapeutics, Inc., Medtronic, Meridigen Biotech Co., Ltd., GW Pharmaceuticals Plc, and Cell Cure Neurosciences Ltd. are some of the key players in the global Cerebral Palsy Treatment Market.
Segmentation
The Cerebral Palsy Treatment Market has been segmented into type, diagnosis, and treatment.
On the basis of type, Cerebral Palsy Treatment Market has been segmented into hypotonic cerebral palsy, spastic cerebral palsy, ataxic cerebral palsy, dyskinetic cerebral palsy, and mixed cerebral palsy.
By diagnosis, CP market segmentation includes imaging tests and others. The imaging tests segment has been further classified into computed tomography, magnetic resonance imaging (MRI), cranial ultrasound, and electroencephalogram.
Based on treatment, Cerebral Palsy Treatment Market has been segmented into cerebral palsy drugs therapy, medication, surgery, and others.
Regional Market Summary
Geographically, the Americas region is anticipated to dominate the global Cerebral Palsy Treatment Market owing to a well-developed healthcare sector, rising prevalence of cerebral palsy and growing healthcare expenditure. Additionally, favorable reimbursement scenario in this region and a relatively large number of research and development (R&D) activities contributes to the growth of the market.
Europe is expected to hold the second largest position in the global Cerebral Palsy Treatment Market. The market growth in this region is attributed to the growing prevalence of cerebral palsy, availability of funds for research, and increasing healthcare expenditure. According to the data stated by the National Institute for Health and Care Excellence (NICE) in 2017, in the UK, it is estimated that 1 in 400 babies are born with cerebral palsy. It also stated that approximately 1,800 children diagnosed with CP each year.
The Cerebral Palsy Treatment Market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, rising prevalence of cerebral palsy and increasing government funding for the healthcare sector.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013,
United States of America
Market Highlights
Facial paralysis is a restriction of the facial movement due to nerve damage. Facial nerve paralysis is characterized by unilateral facial weakness. Some other symptoms include loss of taste, hyperacusis, and decreased salivation and tear secretion.
The global Facial Paralysis Treatment Market is expected to register a CAGR of 6.5% during the forecast period.
Key Players
Some of the key players in the Facial Paralysis Treatment Market are, Boston Scientific, BioControl Medical, Cerebomed, Cyberonics, Astellas Pharma Inc., Sucampo Pharmaceuticals, Inc., and Novartis AG, among others.
Segmentation
The global Facial Paralysis Treatment Market is segmented on the basis of treatment, diagnosis, type, and end-user.
On the basis of type, the market is segmented into, Ramsay Hunt Syndrome, Bell’s Palsy, and Lyme Disease.
On the basis of diagnosis, the market is segmented into electromyography, computerized tomography, and magnetic resonance imaging.
On the basis of treatment, the market is segmented into medications, physical therapy, facial bone surgery and surgery.
On the basis of medication, the market is further sub-segmented into corticosteroids and antiviral drugs.
On the basis of end-user, the market is segmented into hospitals and clinics, specialty centers, and research centers.
Regional Analysis
The Americas dominates the global Facial Paralysis Treatment Market owing to increasing cardiovascular disorders, which eventually leads to the increasing patient population. Additionally, increasing cardiovascular disorder rate is likely to enhance the growth of facial paralysis in the North American region. According to the American Heart Association, 31% of the deaths in the U.S. were due to cardiovascular disorders. Similarly, in 2015, around USD 3.2 trillion were spend in healthcare expenditure in the U.S according to the Center for Disease Control and Prevention. Similarly, in 2015, 1.3% of the U.S. adults were diagnosed with inflammation of facial nerves.
Europe accounts for the second largest market due to increasing cardiovascular disorders and increasing infections. Additionally, the increasing government support and improving healthcare infrastructure along with increasing facial inflammations are driving the growth of the Facial Paralysis Treatment Market in Europe. For instance, Eurostat estimated that over 19.2% of the population in Europe was aged 65 and above. This increasing older population is likely to lead to the increasing patient population. These factors are likely to drive the growth of the Facial Paralysis Treatment Market.
Asia Pacific is the fastest growing market for facial paralysis whose growth is attributed to the rising population and increasing standard of living. Additionally, the increasing healthcare spending and the improved standard of living are likely to drive the growth of the market. India and China are the major contributors to the market growth due to the rapid development of healthcare infrastructure in these regions and the increasing demand for diagnostic services.
On the other hand, the Middle East and Africa is expected to witness a gentle growth due to limited access to the healthcare industry and affordability issues among the population. In the Middle East, the growth of the market is driven by the increasing availability of new and advanced diagnostic and treatment methods for various chronic diseases.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013,
United States of America
Overview:
The global market for the gout market is showing notable potential to record an 8.4% CAGR between 2017 and 2023, which has been marked as the forecast period by Market Research Future (MRFR) in the published report. The report also includes several factors that can make sure the market would grow in the coming years. Gout can be described as a type of arthritis, which is caused by higher uric acid levels in the blood. The disease can be triggered by high blood pressure, high cholesterol, and medications that can spike the presence of uric acid in the blood. Obesity, diet containing a high amount of red meat, consumption of alcohol and smoking can trigger symptoms of gout.
The market is getting better thrust from factors like growing elderly population, transforming lifestyle that includes more sedentary time, advents of better treatment facilities, and government initiatives. However, lack of awareness can make this growth daunting in the coming years.
Competitive Landscape:
The gout market size is having a strong influx of various new players who are giving tough competition to the existing market bigshots. These players are launching their own types of market strategies to make sure that they get good mileage from the market. Their strategic moves often include mergers, new launches, acquisitions, investment, and others. MRFR got these changes recorded in the report to get a closer view of how the market is shaping up. These players are Savient Pharmaceuticals, Takeda Pharmaceutical Company Ltd. Merck & Co. Inc., AstraZeneca plc, Astellas Pharma Inc., Ardelyx, Inc., and Novartis AG.
Segmentation:
The global gout market, as the reports of MRFR suggests, can be studied on the basis of an expert segmentation that includes end-user, treatment, type, and diagnosis. The report focuses on achieving insights from the market and that has initiated a detailed review of each segment.
By type, the report on the gout market can be segmented into tophaceous gout and pseudogout. Both these segments are known for their impact on the market and revenue-generation.
By treatment, the gout market report can be segmented into medications and self-care. The medication segment includes Probenecid, Allopurinol, Febuxostat, Diclofenac, Indomethacin, gout therapeutics, and Ibuprofen. The self-care segment is getting acknowledged by patients across the world.
By diagnosis, the market report on the gout industry can be segmented into blood tests, MRI, X-ray, ultrasound, urine test, CT scan, and others. Growing demand for early diagnosis is expected to set up a significant scope for these tests to fetch high income.
By the end-user, the market report on the gout industry comprises specialty centers, hospitals, and homecare. The home care segment is witnessing a surge as an increasing number of people are opting for the self-care segment.
Regional Analysis:
The North American gout market has a notable chance of making progress in the coming years. The regional market is known for its high expenditure for the research and development sector, which is triggering an increasing number of medicines that are getting launched every year. Major countries inspiring changes are the US and Canada. The regional number of smokers is also quite high, which, along with the high number of geriatric population, can trigger the expansion of the gout market. High number of obese people can also open up spaces for such diseases.
Europe’s market is the second-highest as the regional awareness regarding gout-related problems is quite high. This is getting fostered by the rising number of elderly people. Advanced treatment facilities are also getting introduced owing to which a lot of people are showing interest in getting their disease healed. This is also getting bolstered by a rising amount of investment.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013,
United States of America
Mental health has come into focus due to changing lifestyles of patients and unhealthy work hours. Mental health software and devices utilizes the power of information technology to keep a check on mental or behavioral disorders. The global mental health software and devices market report by Market Research Future (MRFR) focuses on various issues plaguing the market as well as efforts by manufacturers.
Market Outlook
The global mental health software and devices market share can expand from 2017 to 2023 (forecast period) due to the rapid adoption of software by mental health professionals. Change in health practices due to availability of patient records and mental health history can lead to effective management of patients. Collection and analysis of information, elimination of errors, rise in patient income levels, and demand for effective solutions for management of mental health are other drivers of the market.
Development of wearables, changing attitudes of patients and doctors towards information technology, and pressure on hospitals to reduce operational costs can drive the global pharmacies entering mental health market. Real-time monitoring of patient health and provision of advice and medicines via telemedicine can bode well for the market growth in the coming years.
Competition Outlook
Prominent mental health software vendors and device manufacturers profiled in the report include Athena Health, Mindlinc, Mentegram, WRS Health, Kareo, Nextgen Healthcare, ICANotes, Core Solutions, InSync Healthcare Solutions, Compulink, Allscripts, Nuesoft Technologies, NextStep Solutions, Valant, Credible Behavioral Health, Welligent, Raintree Systems, Netsmart, Meditab Software, Orion Health, The Echo Group, Sigmund Software, IBM, TheraNest, Advanced Data Systems, AdvancedMD, Qualifacts, McKesson Corporation, iSalus Healthcare, and Cerner Corporation.
Segmentation Analysis
the global mental health software and devices market is segmented on the basis of solution, deployment, end users and regions.
By component, the market has been segmented by software and devices. The software has been sub-segmented into web based and standalone software.
By functionality, the market has been segmented by clinical, administrative, financial and others. The clinical segment has been categorized into tele-health, electronic health records (EHRs), E-prescribing, clinical decision support, health management, and others. The administrative has been sub segmented into information management, scheduling, workforce management, and others.
The financial has been sub segmented into accounting, revenue cycle management, business intelligence, and others.
Regional Analysis
Region-wise, the global market comprises North America, Middle East & Africa (MEA), Asia Pacific (APAC), and Europe.
North America accounted for the largest market led by the U.S. due to focus on mental health by governments. According to the American Psychological Association in 2019, the number of young U.S. citizens with an increase of mental health disorders has risen due to shift in mood disorders. Other drivers include rapid adoption of technology and development of healthcare infrastructure by governments.
Europe is the second largest region of the market driven by large number of burnout cases and mental health issues of employees. Governments in the region have developed a common platform for collection of mental health issues and records of patients for implementation of good policies as well as welfare schemes. On the other hand, the APAC region is expected to exhibit the fastest growth rate during the forecast period due to being driven by economies of China, India, and Japan. International brands in the region are giving mental health insurance for preventing burnouts and reducing stress in the workplace.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013,
United States of America
Surgical devices are types of instruments that are used for performing numerous forms of surgeries in accordance to the complexity of the surgery like minimally invasive, open, or other types of surgery. The global general surgical devices market is projected to witness an annual compound growth rate of approximately 8.5% during the forecast period between 2017 and 2023.
As per the research conducted by Market Research Future (MRFR), the market is identified to be influenced by numerous factors. The high demand centered around disposable supplies like catheters, syringes, and needles, the growing awareness concerning diseases being transmitted through surgical forms of devices, and favorable government regulations in ensuring or maintaining safety in surgical procedures are expected to stimulate a positive demand for disposable products, thereby pushing the overall general surgical devices market size. An influx of global health initiatives causing advancement in surgical procedures are expected to drive the global general surgical devices market. However, factors like strict government regulations in developing nations and improper reimbursement for surgical devices can cause the market to falter in terms of growth.
Competitive Landscape
The global general surgical devices market comprises of numerous players. A few of them identified in the report are 3M Healthcare (U.S.), Johnson & Johnson Services, Inc. (U.S.), B. Braun Melsungen AG (Germany), Grifols (Spain), SOFINA s.a (Biomérieux) (U.S.), Erbe Elektromedizin GmbH (Germany), Integra LifeSciences (U.S.), Medtronic Plc. (U.S.), Smith & Nephew (U.S.), Stryker Corporation (U.S.), Maquet Holding B.V. & CO. KG. (Germany), CareFusion Corporation (U.S.), Becton, Dickinson and Company (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Conmed Corporation (U.S.), Accuray Incorporated (U.S), Boston Scientific Corporation (U.S.), Ortho-Clinical Diagnostics, Inc. (U.S.), Intuitive Surgical Inc. (U.S.), Siemens Healthcare GmbH (Germany), Cadence Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Virtual Incision Corporation (U.S.), Titan Medical (Canada), Medrobotics Corporation (U.S.), TransEnterix Surgical (U.S.), Olympus Corporations (U.S.), Verb Surgical (U.S.), Meere Company (U.S.), and others.
Market Segmentation
By product, the market includes electrosurgical devices, trocars and access devices, handheld devices, wound closure devices, laparoscopic devices, and others.
By application, the market comprises thoracic surgery, ophthalmology, plastic surgery, orthopedic surgery, surgical instruments, cardiology, neurosurgery, audiology, into wound care, urology and gynecology surgery, and others.
By end-user, the market includes research centers, diagnostic centers, hospitals, academic institutes, clinics, and others.
Regional Analysis
The global general surgical devices market is geographically segmented across the following regions: Europe, America, Asia Pacific, and the Middle East and Africa.
The Americas dominate the global market with the highest share percentage and is expected to further maintain its standings in the forthcoming years. This is due to the vast presence of key players, a striking number of surgical procedures, favorable reimbursement policies, and various initiatives undertaken by the government for providing training sessions as well as access to advanced devices for physicians.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013,
United States of America